11. Clinical Trials

Program on Surgical Control of Hyperlipidemias (POSCH)

$   294

$     —

$     —

$     —

$  —

$  —

$  —

$  —

$  —

$  —

$  —

Infant Heart Surgery:  Central Nervous System Sequelae of Circulatory Arrest

685

582

584

392

75

—

—

—

—

—

—

Women’s Health Study (WHS)

1,473

1,536

1,530

1,594

—

—

—

—

889

—

735

Cardiovascular Risk Factors and the Menopause

494

528

186

—

—

—

—

—

—

—

—

CABG Patch Trial^*

1,171

—

—

—

—

—

—

—

—

—

—

Women’s Antioxidant and Cardiovascular Study (WACS)

501

525

540

556

572

598

592

599

670

—

—

Oral Calcium in Pregnant Women With Hypertension

332

—

—

—

—

—

—

—

—

—

—

Stress Reduction and Atherosclerotic CVD in Blacks

407

40

326

339

360

376

394

—

—

—

—

Enalapril After Anthracycline Cardiotoxicity

724

789

—

—

—

—

—

—

—

—

—

Stress and Anger Management for Blacks With Hypertension

250

—

—

—

—

—

—

—

—

—

—

Estrogen Replacement and Atherosclerosis (ERA) Trial^*

965

1,668

1,017

—

—

—

—

—

—

—

—

Shock Trial:  Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock?

826

874

—

440

362

298

291

296

—

—

—

HDL-Atherosclerosis Treatment Study

445

340

—

326

—

—

—

—

—

—

—

Women’s Estrogen/Progestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-HART)^*

1,196

1,269

1,131

—

32

—

—

—

—

—

—

Mode Selection Trial in Sinus Node Dysfunction (MOST)^*

2,096

1,700

2,879

1,136

154

—

—

—

—

—

—

Antioxidants and Prevention of Early Atherosclerosis^*

603

—

—

—

—

—

—

—

—

—

—

Postmenopausal Hormone Therapy in Unstable Angina

264

271

276

—

—

—

—

—

—

—

—

Estrogen and Graft Atherosclerosis Research Trial (EAGER)^*

488

305

—

361

371

—

—

—

—

—

—

Soy Estrogen Alternative Study (SEA)

217

221

—

—

—

—

—

—

—

—

—

REMATCH Trial^*

1,258

1,798

1,333

825

750

—

—

—

—

—

—

Dietary Patterns, Sodium Intake, and Blood Pressure (DASH Sodium)^{* **}

2,233

3,693

3,646

1,247

151

387

376

395

—

—

—

Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)^*

1,571

1,667

1,709

1,698

1,798

1,412

1,930

—

—

—

—

CVD Risk and Health in Post-Menopausal Phytoestrogen Users

631

662

574

244

—

304

152

—

—

—

—

Treatment of Hypertension With Two Exercise Intensities

359

474

473

481

420

—

—

—

—

—

—

Prevention of Recurrent Venous Thromboembolism (PREVENT)

—

1,242

894

521

543

1,272

—

—

—

—

—

PREMIER:  Lifestyle Interventions for Blood Pressure Control^*

—

2,234

3,425

3,595

2,925

1,505

—

—

—

—

—

Azithromycin and Coronary Events Study (ACES)^*

—

847

2,663

2,182

720

1,254

1,137

—

—

—

—

Antiarrhythmic Effects of N-3 Fatty Acids

—

—

514

542

529

647

—

—

—

—

—

Fatty Acid Antiarrhythmia Trial (FAAT)

—

—

519

605

—

—

—

—

—

—

—

Occluded Artery Trial (OAT)^*

—

—

4,892

5,079

2,604

1,724

1,963

—

—

963

1,452

Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D)^*

—

—

—

3,942

6,515

9,342

8,189

8,265

8,304

8,592

2,647

Hematocrit Strategy in Infant Heart Surgery^*

—

—

—

473

557

596

590

492

—

—

—

Angiotensin-II Blockade in Mitral Regurgitation

—

—

—

—

553

610

629

500

—

—

—

Heart Failure Adherence and Retention Trial (HART)

—

—

—

—

795

1,617

1,453

1,174

861

740

304

Reduction of Triglycerides in Women on HRT

—

—

—

—

708

746

555

544

721

—

625

Women’s Ischemia Syndrome Evaluation (WISE)^{* **}

—

—

—

—

1,502

1,506

1,306

1,303

996

—

—

ACE Inhibition and Novel Cardiovascular Risk Factors

—

—

—

—

—

694

656

602

—

—

—

Heart Failure:  A Controlled Trial Investigating  Outcomes of Exercise (HF-ACTION)^*

—

—

—

—

—

7,471

9,582

7,973

4,483

4,590

2,846

Clinical Trial of Dietary Protein on Blood Pressure

—

—

—

—

—

655

610

612

504

500

—

Home Automatic External Defibrillator Trial (HAT)^*

—

—

—

—

—

3,567

5,433

4,264

1,801

2,115

—

Perioperative Interventional Neuroprotection Trial (POINT)

—

—

—

—

—

553

553

562

572

378

—

Stop Atherosclerosis in Native Diabetics Study (SANDS)^*

—

—

—

—

—

2,410

2,165

2,107

2,324

2,074

197

Surgical Treatment for Ischemic Heart Failure (STICH)^*

—

—

—

—

—

5,709

4,495

1,613

6,082

5,583

9,396

Girls Health Enrichment Multisite Studies (GEMS)^*

—

—

—

—

—

—

2,461

2,400

2,370

1,950

—

Treatment of Depression Following Bypass Surgery

—

—

—

—

—

—

964

1,132

1,181

1,193

885

Weight Loss Maintenance (WLM)^*

—

—

—

—

—

—

3,687

4,368

3,099

4,015

2,151

Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)^*

—

—

—

—

—

—

—

4,343

5,610

4,884

3,307

FREEDOM Trial:  Future Revascularization Evaluation in Patients With Diabetes Mellitus:  Optional Management of Multivessel Disease

—

—

—

—

—

—

—

3,663

4,669

—

5,180

IMMEDIATE Trial:  Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care^*

—

—

—

—

—

—

—

5,170

9,514

10,966

—

AIM HIGH:  Niacin Plus Statin To Prevent Vascular Events^*

—

—

—

—

—

—

—

—

663

6,324

6,018

Claudication:  Exercise Versus Endoluminal Revascularization (CLEVER)^*

—

—

—

—

—

—

—

—

1,368

1,478

1,898

Intervention To Control Obesity in College

—

—

—

—

—

—

—

—

—

677

633

PACEmaker and Beta-Blocker Therapy Post-Myocardial Infarction (PACE-MI)

—

—

—

—

—

—

—

—

—

1,300

4,555

Efficacy of Smoking Quit Line in the Military

—

—

—

—

—

—

—

—

—

—

739

Vest prevention of Early Sudden death Trial (VEST) and PREDiction of ICd Therapies Studies (PREDICTS)^*

—

—

—

—

—

—

—

—

—

—

1,390

Subtotal, Heart and Vascular Diseases

19,483

23,265

29,111

26,578

22,996

45,253

50,163

52,377

56,681

58,312

44,958

Inhaled Beclomethasone To Prevent Chronic Lung Disease^*

436

—

—

—

—

—

—

—

—

—

—

Lung Health Study II^{* **}

3,508

980

—

—

—

—

—

—

—

—

—

Lung Health Study III^{* **}

—

1,997

1,986

1,616

1,672

927

—

—

—

—

—

Asthma Clinical Research Network (ACRN)^{* **}

—

4,934

5,399

5,686

5,705

5,863

—

—

—

—

—

Fetal Tracheal Occlusion for Severe Diaphragmatic Hernia^*

—

—

419

429

181

—

—

—

—

—

—

Scleroderma Lung Study^*

—

—

1,040

1,501

1,761

1,501

1,055

—

—

71

—

Inhaled Nitric Oxide for Prevention of Chronic Lung Disease^*

—

—

—

1,959

1,803

1,764

1,442

1,245

—

—

—

Inhaled Nitric Oxide in Prevention of Chronic Lung Disease^*

—

—

—

1,548

1,742

1,839

1,604

903

—

—

—

Prospective Investigation of Pulmonary Embolism Diagnosis II (PIOPED II)^*

—

—

—

2,190

3,667

3,388

472

—

—

—

—

Randomized Trial To Reduce ETS in Children With Asthma

—

—

—

555

545

468

277

—

—

—

—

Apnea Positive Pressure Long-Term Efficacy Study (APPLES)^*

—

—

—

—

—

3,224

3,021

3,110

3,188

—

1,532

Childhood Asthma Management Program-Continuation Study (CAMP-CS)/Phase II^{* **}

—

—

—

—

—

—

1,489

2,043

2,623

2,750

—

Clinical Trial of Acid Reflux Therapy in Asthma^*

—

—

—

—

—

—

736

783

791

773

662

Impact of CPAP on Functional Outcomes in Milder Obstructive Sleep Apnea (CATNAP)

—

—

—

—

—

—

682

612

608

694

—

Outcomes of Sleep Disorders in Older Men

—

—

—

—

—

—

4,163

4,262

1,390

1,142

910

Supplemental Selenium and Vitamin E and Pulmonary Function

—

—

—

—

—

—

698

610

630

605

561

Improving Asthma Care in Minority Children in Head Start

—

—

—

—

—

—

—

721

826

1,004

779

Adenotonsillectomy for Childhood Sleep Apnea

—

—

—

—

—

—

—

—

—

2,255

2,388

Early Insulin Therapy and Development of ARDS

—

—

—

—

—

—

—

—

—

—

489

Childhood Asthma Management Program—Continuation Study (CAMP-CS)/Phase III^{* **}

—

—

—

—

—

—

—

—

—

—

2,077

Subtotal, Lung Diseases

3,944

7,911

8,844

15,484

17,076

18,974

15,639

14,289

10,056

9,294

9,398

Stroke Prevention in Sickle Cell Anemia (STOP)^*

2,584

2,036

—

293

—

—

—

—

—

—

—

Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG)

270

—

—

—

—

—

—

—

—

—

—

Stroke Prevention in Sickle Cell Anemia (STOP 2)^*

—

—

—

4,200

3,166

3,168

2,320

2,366

—

—

—

Induction of Stable Chimerism for Sickle Cell Anemia

—

—

—

—

489

525

527

551

—

—

—

Sibling Donor Cord Blood Banking and Transplantation

—

—

—

—

1,222

1,224

1,286

1,353

—

—

—

FOCUS

—

—

—

—

—

—

1,639

1,796

2,923

2,446

1,974

Stroke With Transfusions Changing to Hydroxyurea (SWITCH)^*

—

—

—

—

—

—

—

—

3,345

3,932

3,531

Subtotal, Blood Diseases and Resources

2,854

2,036

—

4,493

4,877

4,917

5,772

6,066

6,268

6,378

5,505

Total, NHLBI

$26,281

$33,212

$37,955

$46,555

$44,949

$69,144

$71,574

$82,220

$73,005

$73,984

$59,861

AIM HIGH:  Niacin Plus Statin To Prevent Vascular Events^*

$    6,987,287

$  6,018,096

$  13,005,383

Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI 2D)^*

53,150,028

2,646,947

55,796,975

Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)^*

14,837,498

3,306,675

18,144,173

Claudication:  Exercise Versus Endoluminal Revascularization (CLEVER)^*

2,846,994

1,898,415

4,745,409

Efficacy of Smoking Quit Line in the Military

—

738,869

738,869

FREEDOM Trial:  Future Revascularization Evaluation in Patients With Diabetes Mellitus:  Optimal Management of Multivessel Disease

8,332,457

5,180,309

13,512,766

Heart Failure:  A Controlled Trial Investigating Outcomes of Exercise Training^*

34,099,521

2,846,477

36,945,998

Heart Failure Adherence and Retention Trial (HART)

6,639,821

304,393

6,944,214

Interventions To Control Obesity in College

667,082

633,146

1,300,228

Occluded Artery Trial (OAT)

17,224,514

1,452,378

18,676,892

PACEmaker and Beta-Blocker Therapy Post-Myocardial Infarction  (PACE-MI)^*

1,300,000

4,554,590

5,854,590

Reduction of Triglycerides in Women on HRT

3,275,109

625,001

3,900,110

Stop Atherosclerosis in Native Diabetics Study (SANDS)^*

11,079,036

197,305

11,276,341

Surgical Treatment for Ischemic Heart Failure (STICH)^*

23,482,321

9,395,837

32,878,158

Treatment of Depression Following Bypass Surgery

4,469,703

884,570

5,354,273

Vest prevention of Early Sudden death Trial (VEST) and PREDiction of ICd Therapies Studies (PREDICTS)^*

—

1,389,760

1,389,760

Weight Loss Maintenance (WLM)^*

15,168,042

2,150,858

17,318,900

Women's Health Study (WHS)

16,922,647

735,367

17,658,014

Subtotal, Heart and Vascular Diseases

220,482,060

44,958,993

265,441,053

Acid Reflux Therapy in